Carnosine

An endogenous dipeptide of beta-alanine and L-histidine, concentrated in skeletal muscle and brain, studied for pH buffering, anti-glycation, and carbonyl scavenging; oral doses are rapidly degraded by the serum enzyme carnosinase.

Also referenced as: L-Carnosine, Beta-alanyl-L-histidine

Also appears in: Longevity

COAPublic product evidenceSearch the public certificate ledger for this compoundNo exact compound records are currently indexed under this profile name.→

---

What is Carnosine?

Carnosine (beta-alanyl-L-histidine) is a genuine dipeptide — one of the oldest known, first isolated from meat extract in 1900 — that the body synthesizes itself via carnosine synthase from beta-alanine and L-histidine. It is concentrated at millimolar levels in skeletal muscle and in parts of the brain, and its proposed roles span intracellular pH buffering, metal-ion chelation, antioxidant activity, and protection against protein glycation (Boldyrev et al., Physiological Reviews, 2013).

Unlike most compounds covered on this site, carnosine circulates primarily through the mainstream dietary-supplement channel as capsules rather than through research vendors as lyophilized vials. It shows up in longevity- and anti-aging-oriented catalogs mostly on the strength of its anti-glycation and carbonyl-scavenging literature, and that framing deserves the scrutiny applied below.

How it works

• Intracellular pH buffering. The imidazole ring of carnosine’s histidine residue has a pKa near the physiological range, making carnosine a meaningful proton buffer in skeletal muscle during high-intensity contraction — the property that anchors the entire beta-alanine sports-supplement field (Boldyrev et al., Physiological Reviews, 2013;93(4):1803–1845).
• Anti-glycation. In vitro, carnosine is itself readily glycated by reducing sugars and acts as a sacrificial target: it inhibited glycation and cross-linking of proteins including alpha-crystallin, superoxide dismutase, and catalase, and the glycated dipeptide was non-mutagenic (Hipkiss et al., FEBS Letters, 1995;371(1):81–85). This is the mechanistic basis for the anti-aging positioning.
• Reactive carbonyl scavenging. Carnosine forms covalent adducts with cytotoxic aldehydes generated by lipid peroxidation and glycolysis — 4-hydroxynonenal, acrolein, methylglyoxal — quenching them before they modify proteins (Aldini et al., BioFactors, 2005;24(1–4):77–87).
• Metal chelation and antioxidant activity. Carnosine chelates transition metals, notably zinc and copper, and shows antioxidant behavior in multiple in vitro systems; the zinc–carnosine chelate is itself a drug in Japan (Boldyrev et al., Physiological Reviews, 2013).

The overriding pharmacokinetic caveat sits on top of all of this: human serum contains a dedicated enzyme, carnosinase-1 (CN1, encoded by CNDP1), that rapidly hydrolyzes circulating carnosine back into its constituent amino acids (Teufel et al., Journal of Biological Chemistry, 2003;278(8):6521–6531). In a classic absorption study, intact carnosine was undetectable in plasma after oral ingestion unless carnosinase was inhibited in the collection tubes, even though up to 14% of the dose appeared intact in urine (Gardner et al., Journal of Physiology, 1991;439:411–422). After a 60 mg/kg oral dose, only 8 of 25 healthy subjects showed any measurable plasma carnosine rise, and non-responders had roughly twice the carnosinase protein of responders (Everaert et al., American Journal of Physiology–Renal Physiology, 2012;302(12):F1537–F1544). Rodents lack this serum enzyme, so animal results systematically overstate the exposure an oral dose produces in humans.

Research status

Carnosine has a far deeper human literature than most research-market compounds, and the record is honestly mixed.

Cardiometabolic trials — a real signal, then a string of nulls. A 12-week pilot RCT in 30 non-diabetic adults with overweight or obesity found 2 g/day carnosine prevented the rise in fasting insulin and insulin resistance seen on placebo, with lower two-hour glucose and insulin in participants with impaired glucose tolerance (de Courten et al., Obesity, 2016;24(5):1027–1034). The follow-up program (ClinicalTrials.gov NCT02917928) tested 2 g/day against placebo for 14 weeks in 43 adults with prediabetes or well-controlled type 2 diabetes: carnosine reduced post-load glucose on the oral glucose tolerance test (Hariharan et al., Nutrition, Metabolism and Cardiovascular Diseases, 2024;34(2):485–496), but companion analyses from the same trial reported no effect on blood pressure, endothelial function, arterial stiffness, lipids, or liver and renal outcomes (Saadati et al., Nutrients, 2023;15(22):4835), and no effect on any inflammatory cytokine or adipokine measured (Saadati et al., Nutrients, 2024;16(22):3900). The glucose signal is interesting; the broader cardiovascular and anti-inflammatory story did not hold at this dose and duration.

Autism spectrum disorder — an early positive that did not survive replication. An 8-week double-blind trial of 800 mg/day in 31 children reported significant improvements on the Gilliam Autism Rating Scale (Chez et al., Journal of Child Neurology, 2002;17(11):833–837). A systematic review and meta-analysis of five studies totaling 215 participants subsequently found no significant difference between L-carnosine and placebo on GARS or Childhood Autism Rating Scale measures and concluded that current data do not support its use in this population (Abraham et al., Amino Acids, 2021;53(4):575–585).

N-acetylcarnosine eye drops for cataract — no reliable evidence. The carnosine derivative N-acetylcarnosine has been marketed for decades as a topical cataract treatment. A Cochrane review found only two potentially eligible studies and could not obtain enough information about either to include them, concluding there is currently no convincing evidence that the drops reverse or prevent progression of age-related cataract (Dubois & Bastawrous, Cochrane Database of Systematic Reviews, 2017;2:CD009493).

The exercise field went around the molecule. Because serum carnosinase destroys oral carnosine, sports-performance research loads muscle carnosine indirectly by supplementing beta-alanine, the rate-limiting precursor, which can raise muscle carnosine content substantially over weeks of dosing (Harris et al., Amino Acids, 2006). That literature is evidence about beta-alanine supplementation, not about swallowing carnosine itself — a distinction marketing copy frequently blurs.

Regulatory position. Carnosine is not an approved drug in the United States for any indication; it is sold as a dietary supplement. The zinc–L-carnosine chelate polaprezinc is an approved gastric-ulcer drug in Japan, but that is a distinct chelated compound with its own development history, not evidence for carnosine capsules. Genetics adds a wrinkle rather than an endorsement: a CNDP1 polymorphism that lowers serum carnosinase activity is associated with reduced risk of diabetic nephropathy, which motivates ongoing interest in carnosine and carnosinase-resistant analogs for kidney disease (Everaert et al., 2012, above).

Common dosage forms

• Oral capsules and tablets, typically 250–500 mg of L-carnosine — the dominant format, sold through mainstream supplement channels; clinical trials generally used 1–2 g/day in divided capsule doses.
• Bulk powder, sold by supplement and research-chemical suppliers alike.
• N-acetylcarnosine ophthalmic drops (commonly 1% solutions), marketed for ocular use — a derivative, not carnosine itself.
• Zinc–carnosine chelate capsules, sold as gut-support supplements mirroring the Japanese drug polaprezinc; the chelate is a different chemical entity.
• Lyophilized vials for reconstitution appear occasionally on research-peptide sites, a presentation with essentially no counterpart in the human trial literature, which is almost entirely oral.

This section describes formats only and is not dosing guidance.

Key considerations

• Serum carnosinase is the central honest caveat. Humans (and higher primates) uniquely carry an abundant serum enzyme whose job is to destroy circulating carnosine within minutes. Plasma exposure after oral dosing is brief, small, and strongly genotype-dependent, and rodent studies — where the enzyme is absent — do not translate cleanly. Any claim built on sustained systemic carnosine levels from capsules has this problem to answer.
• The mechanism is better established than the outcomes. Anti-glycation and carbonyl quenching are well documented in vitro, but the best-controlled recent human program found a post-load glucose effect and nothing else: no vascular, lipid, renal, or inflammatory-marker benefit at 2 g/day for 14 weeks.
• Two headline claims have failed formal review. The autism signal from 2002 did not survive meta-analysis, and Cochrane found no convincing evidence for N-acetylcarnosine cataract drops — both are still widely cited in marketing copy.
• Naming confusion is common. Carnosine is routinely conflated with L-carnitine and acetyl-L-carnitine (unrelated compounds), with N-acetylcarnosine (a derivative), with its relatives anserine and homocarnosine, and with beta-alanine (its precursor, which is what the sports literature actually tested). Citations attached to any of these should be checked against the actual compound studied.
• Safety profile in trials is benign but time-limited. Doses up to 2 g/day were well tolerated across the metabolic RCTs over 12–14 weeks; systematic long-term human safety data beyond that window are lacking.